Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel E Sherman

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Nature Reviews. Drug Discovery|May 13, 2017
Combination products: modernizing the regulatory paradigmNina L Hunter, Rachel E Sherman
Health Affairs (Project Hope)|October 11, 2012
Regulatory requirements of the Food and Drug Administration would preclude product claims based on observational researchJoseph P Griffin, Bryant M Godfrey, Rachel E Sherman
The New England Journal of Medicine|November 15, 2013
Expediting drug development--the FDA's new "breakthrough therapy" designationRachel E Sherman, Jun Li, Stephanie Shapley, et al.
Nature Reviews. Drug Discovery|February 25, 2017
Accelerating development of scientific evidence for medical products within the existing US regulatory frameworkRachel E Sherman, Kathleen M Davies, Melissa A Robb, et al.
JAMA|January 23, 2014
Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012Leonard V Sacks, Hala H Shamsuddin, Yuliya I Yasinskaya, et al.
JAMA|May 3, 2012
Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010Robert M Califf, Deborah A Zarin, Judith M Kramer, et al.
Clinical Trials (London, England)|September 17, 2015
The Food and Drug Administration and pragmatic clinical trials of marketed medical productsMonique L Anderson, Joseph Griffin, Sara F Goldkind, et al.
American Heart Journal|July 29, 2014
Independent data monitoring committees: preparing a path for the futureConnie N Hess, Matthew T Roe, C Michael Gibson, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Nature Reviews. Drug Discovery|May 13, 2017
Combination products: modernizing the regulatory paradigmNina L Hunter, Rachel E Sherman
Health Affairs (Project Hope)|October 11, 2012
Regulatory requirements of the Food and Drug Administration would preclude product claims based on observational researchJoseph P Griffin, Bryant M Godfrey, Rachel E Sherman
The New England Journal of Medicine|November 15, 2013
Expediting drug development--the FDA's new "breakthrough therapy" designationRachel E Sherman, Jun Li, Stephanie Shapley, et al.
Nature Reviews. Drug Discovery|February 25, 2017
Accelerating development of scientific evidence for medical products within the existing US regulatory frameworkRachel E Sherman, Kathleen M Davies, Melissa A Robb, et al.
JAMA|January 23, 2014
Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012Leonard V Sacks, Hala H Shamsuddin, Yuliya I Yasinskaya, et al.
JAMA|May 3, 2012
Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010Robert M Califf, Deborah A Zarin, Judith M Kramer, et al.
Clinical Trials (London, England)|September 17, 2015
The Food and Drug Administration and pragmatic clinical trials of marketed medical productsMonique L Anderson, Joseph Griffin, Sara F Goldkind, et al.
American Heart Journal|July 29, 2014
Independent data monitoring committees: preparing a path for the futureConnie N Hess, Matthew T Roe, C Michael Gibson, et al.
Pageof 1